Cancer doctors principally rely on the statistical analysis of large treatment trials, to decide which drugs to use for specific cancers. There is a growing interest, however, in personalised cancer therapy, which involves identifying those treatments which may work best for an individual’s cancer. Chemosensitivity testing is one method of doing this.
Chemosensitivity testing involves testing an individual’s cancer cells in the laboratory to see which drugs demonstrate the best response. It therefore provides guidance about which treatments may be best for the individual in clinical practice.
The RGCC test is a blood test (or sometimes tissue). Tumour cells are identified and isolated from the sample for the following analysis:
• Viability testing of chemotherapy drugs
• Genetic profiling for guidance about targeted therapies eg;
• Viability testing (and identification of mechanisms of action) of natural substances which may be used as part of a complementary treatment strategy .
The results are presented in a written report which your doctor can use to help guide your treatment options and choices.